Novel Nanosensing Technologies Developed for Exosome Detection and Profiling
|
By LabMedica International staff writers Posted on 20 Nov 2019 |

Image: The nano-plasmonic exosome (nPLEX) sensor (Photo courtesy of Massachusetts General Hospital).
Exosomes are extracellular vesicles (EVs) that are produced in the endosomal compartment of most eukaryotic cells. Liquid biopsy technologies have been developed to do high-throughput exosome protein profiling and point-of-care (POC) exosome analysis.
The aim is to develop multiplexed assay systems to streamline the analysis of exosomes and evaluate their clinical utility for cancer management, both as diagnostic tools and to predict disease recurrence. Nanoplasmonic sensors are fabricated to accommodate at most one exosome and individually imaged in real time, enabling the label-free recording of digital responses in a highly multiplexed geometry.
Scientists at the Massachusetts General Hospital (MGH, Boston, MA, USA) and their colleagues developed the nano-plasmonic exosome (nPLEX) sensor, in routine use at MGH, which detects exosome protein levels based on “spectral shifts” (intensity changes) of light through thousands of optimally spaced 200-nanometer (nm) holes. Antibodies against cancer biomarkers get immobilized on the nanopores for capture.
Nanoholes on the sensor are gold and exosomes are labeled by gold nanoparticles for signal amplification. Gold has proven to have the best chemical stability for this type of assay. The device is being manufactured on a glass-based substrate, as silicon wafers proved to be too fragile. The iMEX (integrated magnetic-electrochemical exosome) device, meanwhile, integrates vesicle isolation and detection in a single platform. Target-specific exosomes first get enriched through immunomagnetic selection, for high detection sensitivity. The sensors can be miniaturized and expanded for parallel measurements.
The nPLEX has demonstrated good accuracy and 100 times greater sensitivity than the commonly used enzyme-linked immunosorbent assay (ELISA) and able to detect as few as 3,000 exosomes. The team has also come up with a protein signature for pancreatic ductal adenocarcinoma (PDAC) that is powerful enough for diagnostic purposes, a combination of EGFR (epidermal growth factor receptor), EpCAM, MUC1, GPC1 and WNT2. As demonstrated in a prospective study involving more than 100 patients and age-matched controls, as the tumors shrink the biomarker combination gets lower and lower.
The scientists have also used nPLEX technology to show how exosome protein expression of cancer cells changes with drug treatment. Discovery of these unique, drug-dependent protein signatures suggests the exosome screening assay will be a potentially powerful molecular screening tool. Hyungsoon Im, PhD, an assistant professor of radiology and a senior author of the study, said, “The screening assay could be incorporated into point–of–care (POC) instruments for more rigorous testing of different drugs in different settings. The study was presented at the 2019 Next Generation Dx Summit held August 20-22, 2019 in Washington, DC, USA.
Related Links:
Massachusetts General Hospital
The aim is to develop multiplexed assay systems to streamline the analysis of exosomes and evaluate their clinical utility for cancer management, both as diagnostic tools and to predict disease recurrence. Nanoplasmonic sensors are fabricated to accommodate at most one exosome and individually imaged in real time, enabling the label-free recording of digital responses in a highly multiplexed geometry.
Scientists at the Massachusetts General Hospital (MGH, Boston, MA, USA) and their colleagues developed the nano-plasmonic exosome (nPLEX) sensor, in routine use at MGH, which detects exosome protein levels based on “spectral shifts” (intensity changes) of light through thousands of optimally spaced 200-nanometer (nm) holes. Antibodies against cancer biomarkers get immobilized on the nanopores for capture.
Nanoholes on the sensor are gold and exosomes are labeled by gold nanoparticles for signal amplification. Gold has proven to have the best chemical stability for this type of assay. The device is being manufactured on a glass-based substrate, as silicon wafers proved to be too fragile. The iMEX (integrated magnetic-electrochemical exosome) device, meanwhile, integrates vesicle isolation and detection in a single platform. Target-specific exosomes first get enriched through immunomagnetic selection, for high detection sensitivity. The sensors can be miniaturized and expanded for parallel measurements.
The nPLEX has demonstrated good accuracy and 100 times greater sensitivity than the commonly used enzyme-linked immunosorbent assay (ELISA) and able to detect as few as 3,000 exosomes. The team has also come up with a protein signature for pancreatic ductal adenocarcinoma (PDAC) that is powerful enough for diagnostic purposes, a combination of EGFR (epidermal growth factor receptor), EpCAM, MUC1, GPC1 and WNT2. As demonstrated in a prospective study involving more than 100 patients and age-matched controls, as the tumors shrink the biomarker combination gets lower and lower.
The scientists have also used nPLEX technology to show how exosome protein expression of cancer cells changes with drug treatment. Discovery of these unique, drug-dependent protein signatures suggests the exosome screening assay will be a potentially powerful molecular screening tool. Hyungsoon Im, PhD, an assistant professor of radiology and a senior author of the study, said, “The screening assay could be incorporated into point–of–care (POC) instruments for more rigorous testing of different drugs in different settings. The study was presented at the 2019 Next Generation Dx Summit held August 20-22, 2019 in Washington, DC, USA.
Related Links:
Massachusetts General Hospital
Latest Molecular Diagnostics News
- Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
- Genome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
- Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
- Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
- Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
- FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
- Whole Transcriptome Analysis Expands Understanding of Cancer Gene Fusions
- Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
- Genetic Test Improves Risk Prediction for Open-Angle Glaucoma
- Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
- Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
- Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
Histopathology image analysis plays a central role in cancer diagnosis, but tumor tissue can vary considerably across different regions of the same specimen. Pathologists examine cellular morphology, nuclear... Read more
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







